Last update Jan. 21, 2021
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C20H17ClN2O3 is Ketazolam in Molecular formula.
Is written in other languages:Variable | Value | Unit |
---|---|---|
Oral Bioavail. | Alta - High | % |
Molecular weight | 369 | daltons |
Protein Binding | 93 | % |
pKa | 14.2 | - |
Tmax | 12 | hours |
T½ | 52 (26 - 200) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Long-acting benzodiazepine with anxiolytic and muscle relaxing effect.
Indicated in the control of anxiety and muscle spasticity.
Oral administration once or twice a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data does not make it easy to accurately predict possible transfer to breastmilk, because while its high percentage of protein binding would prevent it, its high pKA and very long half-life would facilitate it.
It has very few bibliographical references and is marketed in few countries.
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and adequate feeding of the infant.
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).